Archive · 13 Jan 2026
Metropolis Healthcare Launches Centre of Genomics
Metropolis Healthcare has opened a new Centre of Genomics to help with very precise medical tests.
This center will use advanced technology and smart computer programs to study genes and help doctors treat serious illnesses like cancer, problems with having babies, brain diseases, and rare conditions.
They plan to add more than 500 new tests in the next few years.
The company is also growing fast, with a 26% increase in money made last quarter.
They are using special machines to make their tests more accurate and are working with other companies to do important medical research.
Metropolis Healthcare launched a Centre of Genomics on January 13 to enhance precision diagnostics and genomic research in India.
The center is supported by two CAP-accredited genomics laboratories in Mumbai and Delhi NCR.
It will focus on high-impact clinical areas including oncology, reproductive health, neurology, transplant immunology, and rare diseases.
Metropolis plans to expand its genomic portfolio to over 500 advanced tests within the next two to three years.
The company has deployed Illumina’s NovaSeq X Series sequencing platform to enhance genomic analysis and supports AI-driven analytics and clinical trials.
- Who
- Metropolis Healthcare Limited
- What
- Launched a Centre of Genomics
- When
- January 13
- Where
- India (Mumbai and Delhi NCR)
- Why
- To scale precision diagnostics, molecular testing, and genomic research
- Company
- Metropolis Healthcare Limited
- Launch Date
- January 13
- Key Areas
- Oncology, Reproductive Health, Neurology, Transplant Immunology, Rare Diseases
- Current Tests
- 220 validated assays
- Planned Expansion
- 500 advanced tests in 2-3 years
- Technology Used
- Illumina’s NovaSeq X Series
- Revenue Growth
- 26% year-on-year in Q3
- Share Price
- ₹1,876.30 (as of 11:49 am)